دورية أكاديمية
Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024.
| العنوان: | Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024. |
|---|---|
| المؤلفون: | Link-Gelles R, Ciesla AA, Mak J, Miller JD, Silk BJ, Lambrou AS, Paden CR, Shirk P, Britton A, Smith ZR, Fleming-Dutra KE |
| المصدر: | MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2024 Feb 01; Vol. 73 (4), pp. 77-83. Date of Electronic Publication: 2024 Feb 01. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: U.S. Centers for Disease Control Country of Publication: United States NLM ID: 7802429 Publication Model: Electronic Cited Medium: Internet ISSN: 1545-861X (Electronic) Linking ISSN: 01492195 NLM ISO Abbreviation: MMWR Morb Mortal Wkly Rep Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Atlanta, GA : U.S. Centers for Disease Control Original Publication: [Atlanta] U. S. Dept. of Health, Education, and Welfare, Public Health Service, Center for Disease Control. |
| مواضيع طبية MeSH: | COVID-19 Vaccines* , COVID-19*/diagnosis , COVID-19*/epidemiology , COVID-19*/prevention & control, United States/epidemiology ; Adult ; Humans ; Adolescent ; Vaccine Efficacy ; SARS-CoV-2 |
| مستخلص: | On September 12, 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (updated) COVID-19 vaccination with a monovalent XBB.1.5-derived vaccine for all persons aged ≥6 months to prevent COVID-19, including severe disease. During fall 2023, XBB lineages co-circulated with JN.1, an Omicron BA.2.86 lineage that emerged in September 2023. These variants have amino acid substitutions that might increase escape from neutralizing antibodies. XBB lineages predominated through December 2023, when JN.1 became predominant in the United States. Reduction or failure of spike gene (S-gene) amplification (i.e., S-gene target failure [SGTF]) in real-time reverse transcription-polymerase chain reaction testing is a time-dependent, proxy indicator of JN.1 infection. Data from the Increasing Community Access to Testing SARS-CoV-2 pharmacy testing program were analyzed to estimate updated COVID-19 vaccine effectiveness (VE) (i.e., receipt versus no receipt of updated vaccination) against symptomatic SARS-CoV-2 infection, including by SGTF result. Among 9,222 total eligible tests, overall VE among adults aged ≥18 years was 54% (95% CI = 46%-60%) at a median of 52 days after vaccination. Among 2,199 tests performed at a laboratory with SGTF testing, VE 60-119 days after vaccination was 49% (95% CI = 19%-68%) among tests exhibiting SGTF and 60% (95% CI = 35%-75%) among tests without SGTF. Updated COVID-19 vaccines provide protection against symptomatic infection, including against currently circulating lineages. CDC will continue monitoring VE, including for expected waning and against severe disease. All persons aged ≥6 months should receive an updated COVID-19 vaccine dose. Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed. |
| References: | MMWR Morb Mortal Wkly Rep. 2023 Feb 03;72(5):125-127. (PMID: 36730050) Lancet Infect Dis. 2023 May;23(5):556-567. (PMID: 36681084) MMWR Morb Mortal Wkly Rep. 2022 Apr 29;71(17):606-608. (PMID: 35482574) Open Forum Infect Dis. 2023 Apr 13;10(5):ofad187. (PMID: 37213428) MMWR Morb Mortal Wkly Rep. 2023 Oct 20;72(42):1140-1146. (PMID: 37856366) Lancet Infect Dis. 2024 Feb;24(2):e82. (PMID: 38184005) MMWR Morb Mortal Wkly Rep. 2023 Feb 03;72(5):119-124. (PMID: 36730051) PLoS One. 2022 Oct 3;17(10):e0275150. (PMID: 36190984) |
| المشرفين على المادة: | 0 (COVID-19 Vaccines) |
| SCR Organism: | SARS-CoV-2 variants |
| تواريخ الأحداث: | Date Created: 20240201 Date Completed: 20240205 Latest Revision: 20240207 |
| رمز التحديث: | 20240207 |
| مُعرف محوري في PubMed: | PMC10843065 |
| DOI: | 10.15585/mmwr.mm7304a2 |
| PMID: | 38300853 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1545-861X |
|---|---|
| DOI: | 10.15585/mmwr.mm7304a2 |